Printer Friendly

COPLEY PHARMACEUTICAL ANNOUNCES THE APPROVAL OF FLUPHENAZINE HYDROCHLORIDE ELIXIR USP

 CANTON, Mass., April 29 /PRNewswire/ -- Copley Pharmaceutical, Inc. (NASDAQ: CPLY) announced today the approval of Fluphenazine Hydrochroride Elixir, the generic version of Prolixin(R) Elixir (Apothecon, a Bristol-Myers Squibb Company).
 Fluphenazine Hydrochloride is intended for the treatment of schizophrenia, and expands our line of anti-psychotic solutions, including Doxepin, Haloperidol, Thioridazine, and Thiothixene. This line of products will be a valuable addition to our Managed Care line of products.
 Copley Pharmaceutical, Inc. develops, manufactures and markets a broad range of off-patent prescription and over-the-counter pharmaceutical products in a variety of dosage forms and strengths, including extended-release products. The company markets its products to distributors, retail chains, wholesalers, hospitals, government agencies and managed care entities.
 -0- 4/29/93
 /CONTACT: Dr. Mark Hirsh, executive vice president -- marketing & business development, 800-325-6111 or 617-821-6111/
 (CPLY)


CO: Copley Pharmaceutical, Inc. ST: Massachusetts IN: MTC SU: PDT

DD -- NE016 -- 2809 04/29/93 15:35 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 29, 1993
Words:150
Previous Article:C. MICHAEL JACOBI NOMINATED TO BOARD OF WEBSTER
Next Article:PLAYBOY ELECTS REBECCA S. MASKEY SENIOR VICE PRESIDENT FINANCE AND TREASURER
Topics:


Related Articles
COPLEY PHARMACEUTICAL ANNOUNCES THE APPROVAL OF LIDOCAINE HYDROCHLORIDE JELLY 2 PERCENT
COPLEY PHARMACEUTICAL ANNOUNCES THE APPROVAL OF METHAZOLAMIDE TABLETS USP, 25 & 50 MG
COPLEY PHARMACEUTICAL, INC. RECEIVES FDA APPROVAL FOR MEBENDAZOLE CHEWABLE TABLETS, 100 MG
COPLEY PHARMACEUTICAL, INC. BEGINS SHIPPING TWO NEW PRODUCTS
COPLEY PHARMACEUTICAL ANNOUNCES AVAILABILITY OF HYDROXYCHLOROQUINE TABLETS AND APPROVAL OF CAPTOPRIL TABLETS
FIRST GENERIC DRUG FOR PINWORM RELEASED FOR U.S. MARKET, COPLEY PHARMACEUTICAL ANNOUNCES
FIRST ALTERNATIVE FOR CORTENEMA RELEASED FOR U.S. MARKET
COPLEY PHARMACEUTICAL RECEIVES FDA APPROVAL TO MARKET CAPTOPRIL TABLETS
COPLEY PHARMACEUTICAL, INC. RECEIVES FDA APPROVAL TO MARKET NADOLOL TABLETS
FDA Approves Copley Pharmaceutical's ANDA for Procainamide HCl 1000 mg Tablets

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters